Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.
about
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitusSLC transporters as therapeutic targets: emerging opportunitiesSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic AgentsPotentiation of insulin-mediated glucose lowering without elevated hypoglycemia risk by a small molecule insulin receptor modulatorObesity: Current and potential pharmacotherapeutics and targets.Sodium-glucose transporter-2 (SGLT2; SLC5A2) enhances cellular uptake of aminoglycosides.The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet.Sodium-glucose co-transporter inhibition in the treatment of diabetes: sweetening the potLong-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes.Structural selectivity of human SGLT inhibitors.Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 DiabetesLX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models.Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.Thyroid hormone treatment decreases hepatic glucose production and renal reabsorption of glucose in alloxan-induced diabetic Wistar rats.A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatmentEnantioselective synthesis of beta-(3-hydroxypyrazol-1-yl) ketones using an organocatalyzed Michael addition reactionRole of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies.Sodium-glucose transport: role in diabetes mellitus and potential clinical implications.Emergence of promising therapies in diabetes mellitus.Diabetes area participation analysis: a review of companies and targets described in the 2008 - 2010 patent literature.SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus.SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.A novel strategy for the treatment of diabetes mellitus - sodium glucose co-transport inhibitors.Red carpeting the newer antidiabetics.Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.SGLT2 inhibition: a novel prospective strategy in treatment of diabetes mellitus.The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors.Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport.Clinical implication of SGLT2 inhibitors in type 2 diabetes.Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies.
P2860
Q21195757-FA858913-F227-4F30-BF97-5A6ADCF61ECCQ27014726-5DE2F6A4-B2CD-4D9F-B493-B9E8AA61BA2DQ28072765-36EAE4F6-0C24-48F9-A6B8-37F80C095742Q28074843-35291582-B165-425F-B75A-174C7C41E2CAQ28544827-5945D3E8-9F8F-4C43-B61C-26CB0F03A01BQ30243992-2A8829A3-B662-4502-B116-5B1A3DFDCAAAQ30429061-8D1BA360-8B6C-4DD6-8F86-E46279DA8DFEQ30663494-85ACF5BA-BEFB-463C-BCC1-D48B460E19E8Q33451134-25582973-DD51-47DF-B7DF-DD543C571BCDQ33857698-4D2D4114-C8F0-4686-A2BB-E6FACBC2D79DQ35192356-A5E59A07-2838-4AC0-A037-CB8BC5B08B53Q35194026-D5F1C90B-E36E-409E-917A-D9FDB0B24E7EQ35548033-46F9955D-ED2C-422D-9CFE-7AF29DDD90C8Q35895528-CC8BF46B-3797-447B-BAA3-02CCC3EC6D43Q35909303-5BB66751-59D7-412F-B1BD-34F302C7DA3CQ36105649-18CE0D0E-674C-4B93-8CBE-A7A507438B2BQ36179371-406AA706-C5E5-45C4-B319-5680F1154D4BQ36745809-AEABE5C4-8855-4F50-9E69-BB07A9F5C945Q36929947-BD253561-B72A-4721-8791-C00042B4D5DBQ37219076-D9A9F673-773B-47E3-B460-6E6E34826D50Q37286814-65F5960B-4A91-4E01-851D-4550AF442484Q37319128-C18965DF-2015-4035-BF1B-657054A1EF29Q37363203-F8F8B841-BE7D-474D-BF48-A73A633E5576Q37650996-B0A76124-81FF-409A-A433-4B9EF0C43432Q37764285-A6BC5C11-C61E-4325-8D97-70A26D8EF216Q37779684-BEAA27E6-9F14-4DBF-BFAF-71916A9F059BQ37810292-F2E64B1A-16D0-4B4E-AE7C-D8FA632E644DQ37872125-131A1C12-10A2-4401-B7CF-55D4E1452637Q37960123-3D8125C5-212F-4D47-9CA3-189462C283F0Q37981884-75865177-302A-4407-BCCE-D36E460E36C8Q38007487-77123F3F-8D28-47F8-BD62-926F56F73AFDQ38013105-FF75BB65-5E35-41F3-8784-05777FED3206Q38036770-38103E05-22CD-4543-8FB6-1F52F4206633Q38075117-C49B7718-48D4-4B49-B78F-278662324FEAQ38084363-8F2D8DB6-CF5D-4DAB-AF04-D2BB7569E459Q38126109-417224CD-A31B-49A6-AC8F-263A5F5F3A22Q38130748-97BF803A-F558-4781-90C8-47AF2EE0C967Q38201162-89953EAA-1441-4AFE-908B-DF5B33820F2EQ38221980-A5A2672B-37E8-4F5A-96CE-91675C08E8B4Q38226897-EFDF7A32-2926-4835-9A43-1C2E040E3330
P2860
Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Remogliflozin etabonate, in a ...... tic efficacy in rodent models.
@en
Remogliflozin etabonate, in a ...... tic efficacy in rodent models.
@nl
type
label
Remogliflozin etabonate, in a ...... tic efficacy in rodent models.
@en
Remogliflozin etabonate, in a ...... tic efficacy in rodent models.
@nl
prefLabel
Remogliflozin etabonate, in a ...... tic efficacy in rodent models.
@en
Remogliflozin etabonate, in a ...... tic efficacy in rodent models.
@nl
P2093
P356
P1476
Remogliflozin etabonate, in a ...... tic efficacy in rodent models.
@en
P2093
Hideki Fujikura
Ikumi Nakashima
Kenji Katsuno
Masayuki Isaji
Yoshikazu Fujimori
Yukiko Ishikawa-Takemura
P304
P356
10.1124/JPET.108.140210
P407
P577
2008-06-26T00:00:00Z